In the RIP-Tag2 mouse model of PanNET, a model also used for anti-angiogenesis research, brivanib, a dual FGF/VEGF inhibitor, produced enduring tumor stasis and angiogenic blockade following the failure of DC101 (an anti-VEGFR2 monoclonal antibody) or sorafenib [35]. This evidence concerns the gene VEGFA and neoplasm.